AstraZeneca, Daiichi Sankyo's Datopotamab Deruxtecan Plus Imfinzi With Or Without Chemotherapy Demonstrated Objective Response Rates Of 77% And 50% And Disease Control Rates Of 92% And 93%, Respectively In Untreated Lung Cancer Patients
Portfolio Pulse from Benzinga Newsdesk
AstraZeneca and Daiichi Sankyo's Datopotamab Deruxtecan combined with Imfinzi, with or without chemotherapy, showed objective response rates of 77% and 50% and disease control rates of 92% and 93% respectively in untreated lung cancer patients. The trial included patients with previously untreated advanced or metastatic non-small cell lung cancer without actionable genomic alterations.
September 11, 2023 | 8:29 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
AstraZeneca's drug, developed in partnership with Daiichi Sankyo, showed promising results in lung cancer trial, which could potentially boost its market position in the oncology sector.
Positive trial results often lead to increased investor confidence and potential market growth, which could positively impact AstraZeneca's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Daiichi Sankyo's collaboration with AstraZeneca on a lung cancer drug showed promising results, potentially strengthening its position in the oncology market.
Positive trial results often lead to increased investor confidence and potential market growth, which could positively impact Daiichi Sankyo's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100